B cell lymphopenia, hypogammaglobulinemia, and recurrent infections are highly penetrant clinical features of most patients with IKZF1 mutations (Hoshino et al., 2017; Kuehn et al., 2022; Yamashita and Morio, 2021). Here, IKZF1 is linked to agammaglobulinemia.